85.04
-1.49(-1.72%)
Currency In USD
Address
1801 Augustine Cut-Off
Wilmington, DE 19803
United States of America
Phone
302 498 6700
Website
Sector
Healthcare
Industry
Biotechnology
Employees
2617
First IPO Date
November 04, 1993
| Name | Title | Pay | Year Born |
| Mr. Herve Hoppenot | Chairman, President & Chief Executive Officer | 3.6M | 1960 |
| Ms. Paula J. Swain | Executive Vice President of Human Resources | 611,916 | 1958 |
| Ms. Christiana Stamoulis M.B.A. | Executive Vice President & Chief Financial Officer | 1.4M | 1971 |
| Dr. Steven H. Stein M.D. | Executive Vice President & Chief Medical Officer | 1.56M | 1967 |
| Dr. Pablo J. Cagnoni M.D., Ph.D. | President and Head of Research & Development | 2.04M | 1963 |
| Mr. Ben Strain | Head of Investor Relations | 0 | N/A |
| Mr. Michael James Morrissey | Executive Vice President & Head of Global Technical Operations | 0 | 1964 |
| Mr. Thomas Tray | Vice President of Finance, Chief Accounting Officer & Controller | 0 | 1978 |
| Ms. Sheila A. Denton J.D. | Executive Vice President, General Counsel & Corporate Secretary | 0 | 1966 |
| Ms. Pamela M. Murphy | Vice President of Investor Relations & Corporate Communications | 0 | 1951 |
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.